Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Expenses (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Operating Expenses for 4 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 88.66% year-over-year to $7.0 million, compared with a TTM value of $125.7 million through Sep 2025, down 45.73%, and an annual FY2024 reading of $212.4 million, down 25.37% over the prior year.
  • Operating Expenses was $7.0 million for Q3 2025 at Atara Biotherapeutics, down from $14.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $95.5 million in Q1 2022 and bottomed at $7.0 million in Q3 2025.
  • Average Operating Expenses over 4 years is $61.5 million, with a median of $64.2 million recorded in 2023.
  • Peak annual rise in Operating Expenses hit 1.27% in 2025, while the deepest fall reached 88.66% in 2025.
  • Year by year, Operating Expenses stood at $75.8 million in 2022, then dropped by 15.24% to $64.2 million in 2023, then dropped by 29.99% to $45.0 million in 2024, then tumbled by 84.37% to $7.0 million in 2025.
  • Business Quant data shows Operating Expenses for ATRA at $7.0 million in Q3 2025, $14.4 million in Q2 2025, and $59.3 million in Q1 2025.